References
- King S B. The nitric oxide producing reactions of hydroxyurea. Curr Med Chem 2003; 10: 437–452
- Boyd A S, Nelder K H. Hydroxyurea therapy. J Am Acad Dermatol 1991; 25: 518–524
- Fishbein W N, Carbone P P. Hydroxyurea: Mechanism of action. Science 1963; 142: 1069–1070
- Nyholm S, Thelander L, Grasland A. Reduction and loss of iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry 1993; 32: 11569–11574
- Garcia-Manero G, Faderi S, O'Brien S, Cortes J, Talpaz M, Kantarjian H M. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 2003; 96: 437–457
- Wang P G, Xian M, Tang X, Wu X, Wen Z, Cai T, et al. Nitric oxide donors: chemical activities and biological applications. Chem Rev 2002; 102: 1034–1091
- King S B. Nitric oxide production from hydroxyurea. Free Radic Biol Med 2004; 37: 737–744
- Huang J, Sommers E M, Kim-Shapiro D B, King S B. Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. J Am Chem Soc 2002; 124: 3473–3480
- Jiang J, Jordan S J, Barr D P, Gunther M R, Meada H, Mason R P. In vivo production of nitric oxide in rats after administration of Hydroxyurea. Mol Pharmacol 1997; 52: 1081–1086
- Craven P A, DeRubertis F R. Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation. J Biol Chem 1978; 253: 8433–8443
- Mellion B T, Ignarro L J, Ohlstein E H, Pontecorvo E G, Hyman A L, Kadowitz P J. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946–955
- Radomski M W, Palmer R M, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639–646
- Severina I S. Soluble platelet guanylate cyclase: significance of heme in regulating enzymatic activity and the role of the enzyme in platelet aggregation. Biokhimiia 1994; 59: 325–339
- Moro M A, Russel R J, Cellek S, Lizasoain I, Su Y, Darley-Usmar V M, et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996; 93: 1480–1485
- Eigenthaler M, Ullrich H, Geiger J, Horstrup K, Honig-Liedl P, Wiebecken D, et al. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. J Biol Chem 1993; 268: 13521–13526
- Garthwaite J, Southam E, Boulton C L, Nielsen E B, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one. Mol Pharmacol 1995; 48: 184–188
- Conran N, Oresco-Santos C, Acosta H C, Fattori A, Saad S T, Costa F F. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br J Haematol 2004; 124: 547–554
- Cokic V P, Smith R D, Beleslin-Cokic B B, Njoroge J M, Miller J L, Gladwin M T, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111: 231–239
- Rodriguez G I, Kuhn J G, Weiss G R, Hilsenbeck S G, Eckardt J R, Thurman A, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 1998; 91: 1533–1541